BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Atherotech, Inc. Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting


5/13/2010 8:19:18 AM

BIRMINGHAM, Ala., May 12 /PRNewswire/ -- Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

The VAP Test is the only advanced lipid test that routinely reports directly measured LDL-C, which is included in the 22 separate components of cholesterol -- all reported at no additional cost. Cholesterol subclasses include Lp(a), apoB, apoAI, and the apoB/apoAI ratio, making the VAP Test the only lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology. The advanced lipid profile also identifies markers of metabolic syndrome, often associated with early diabetes.

Members of Atherotech's Medical Advisory Board and NLA Scientific Sessions program chairs, Michael H. Davidson, M.D., and Peter P. Toth, M.D., Ph.D., will lead colleagues at the Third Annual NLA Summit on HDL Therapeutics. The May 14 program will assess current HDL-C therapy options as well as those in development and discuss insight from recent clinical trials.

"Much is to be learned at this year's NLA gathering, including new research, ways to advance the public's knowledge of lipids and therapeutic advances in lipidology," said Toth, a diplomate of the American Board of Clinical Lipidology and president of the Midwest Lipid Association.

Atherotech provides physicians with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Cardiometabolic testing available through Atherotech includes C-Reactive Protein (hsCRP), LpPLA2, apoE genotype, NT-proBNP, Cystatin-C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.

Atherotech representatives will be available to discuss new research, the VAP Test and cardiometabolic test options throughout the conference. Blood draws will be provided to qualified attendees during regular exhibit hours. Unlike the standard lipid profile, the VAP Test directly measures LDL, therefore fasting is not required.

"Physicians and lipidologists can learn firsthand the power of the VAP Cholesterol Test and how it provides a much greater predictive value for cardiovascular disease," Atherotech Chief Medical Officer Michael E. Cobble, M.D. said.

For more information on the NLA Scientific Sessions, visit www.lipid.org. For more information on the VAP Test, visit www.atherotech.com or call 877.901.8510.

About Atherotech Inc.

Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.

SOURCE Atherotech Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES